Home / Article

Kamada Sees Record Growth and Expects Double-Digit Expansion in 2025

Burstable News - Business and Technology News March 14, 2025
By Burstable News Staff
Read Original Article →
Kamada Sees Record Growth and Expects Double-Digit Expansion in 2025

Summary

Biopharma company Kamada Ltd. reports exceptional financial performance in 2024, with record revenues and profitability, and projects continued growth through strategic global expansion and innovative plasma-derived therapeutics.

Full Article

Kamada Ltd., a specialty plasma-derived therapeutics company, reported record financial results for 2024 and outlined an ambitious growth strategy for 2025, projecting continued double-digit expansion and increased market presence.

The company achieved an annual revenue of $161 million in 2024, representing a 13% increase from the previous year. Net income reached $14.5 million, a substantial 75% improvement over 2023, while maintaining robust operational efficiency with an adjusted EBITDA of $34.1 million, up 42% year-over-year.

Management anticipates total 2025 revenue between $178 million and $182 million, signaling approximately 12% growth. Key revenue drivers include six FDA-approved plasma-derived specialty therapies, with particular emphasis on KEDRAB, a human rabies immune globulin, and CYTOGAM, an immunoglobulin product for organ transplant patients.

The company is also expanding its biosimilar portfolio in Israel, expecting to launch 1-3 products annually, with potential annual sales of $15-20 million within five years. Additionally, Kamada is developing an inhaled alpha-1 antitrypsin therapy targeting a market potentially exceeding $2 billion.

Strategic global expansion is another focus, highlighted by a recent $25 million contract to supply rabies and anti-varicella treatments in South America through 2027. The company is also opening a third plasma collection facility in San Antonio, Texas, expected to contribute $8-10 million in annual revenue and reduce dependence on third-party suppliers.

CEO Amir London emphasized the company's commitment to business development and in-licensing opportunities to accelerate revenue growth and ensure long-term sustainability. These strategic moves position Kamada to capitalize on the critical role of plasma-derived medicines in addressing rare and serious medical conditions.

QR Code for Content Provenance

This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire

Article Control ID: 46431